Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

249818.pdf (685.21 KB)

Document type

Article

Version

Published version

Publication date

2022-03-14

Publication license

cc-by-nc (c) Ortiz-Gracia, A. et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/219063

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1136/archdischild-2021-322996

Abstract

Background: Ganciclovir/valganciclovir is currently indicated during the first 6 months of life in symptomatic children with congenital cytomegalovirus (CMV) infection. However, this treatment may have the potential to induce mitochondrial toxicity due to off-target inhibition of DNA-polymerases. Similar anti-HIV drugs have been associated with mitochondrial toxicity but this has never been explored in CMV. Objective: To determine the potential mitochondrial toxicity profile at the genetic, functional and biogenesis level in peripheral blood mononuclear cells from a cohort of newborns and infants with symptomatic congenital CMV infection (treated with valganciclovir, untreated and uninfected controls). Design: Longitudinal, observational and controlled study. Setting and patients: Subjects were recruited at the tertiary referral Hospital Sant Joan de Déu and experiments were conducted at IDIBAPS-Hospital Clínic of Barcelona, Spain. CMV-infected newborns underwent comprehensive monthly clinical follow-up. Methods: Mitochondrial parameters, audiometry and neurological assessment were measured at baseline, 3-6 and 12 months after inclusion in the study. The Kruskal-Wallis test for k-independent samples and Friedman tests for repeated measurements were applied. Results: Complex IV, citrate synthase enzymatic activities and mtDNA remained preserved in congenital CMV-infected infants treated with valganciclovir compared with controls (p>0.05 in all cases). Conclusions: No evidence of mitochondrial toxicity was found in infants treated with valganciclovir for congenital CMV.

Subject

Infants, Infeccions per citomegalovirus, Medicaments antivírics

Subject (English)

Children, Cytomegalovirus infections, Antiviral agents

Citation

Collections

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citation

ORTIZ RODRIGO, Alba, et al. Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir. Archives of Disease in Childhood. 2022. Vol. 107, num. 7, pags. 686-691. ISSN 0003-9888. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/219063

Export metadata

JSON - METS

Share record